¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"Vasoactive Intestinal Peptide Tumor"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
  • intestinal volvulus
    Àå¿°ÀüÁõ(íóÒºï®ñø).
  • intestinal volvulus
    Àå¿°ÀüÁõ(Àå³äÀüÁõ).
  • intestinal wall
    À庮(íóÛú).
  • juxta-intestinal lymph nodes
    ¼ÒÀå¿·¸²ÇÁÀý
  • normal intestinal flora
    Àå³»Á¤»ó¼¼±ÕÃÑ
  • posterior intestinal portal
    µÚÀå¹®, ÈÄÀå¹®(ý­ Ú¦).
  • rotation of intestinal loop
    âÀÚ°í¸®È¸Àü
  • small intestinal biopsy
    ¼ÒÀå»ý°Ë(á³ ßæËþ).
  • acinic cell tumor
    ¼±¹æ¼¼Æ÷Á¾(¡­á¬øàðþ)
  • acoustic tumor
    û½Å°æÁ¾¾ç
  • adenomatoid tumor
    ¼±¾çÁ¾¾ç
  • adenomatoid tumor
    ¼±Á¾¾çÁ¾¾ç(àÍðþåÆðþåË), À¯¼±Á¾Á¾¾ç(×¾àÍðþðþåË)
  • adenomatoid tumor, tubal
    ¼±Á¾¾çÁ¾¾ç(àÍðþåÆðþåË), ³­°ü(Ñëη)ÀÇ
  • adrenal cortex tumor
    ºÎ½ÅÇÇÁúÁ¾¾ç
  • adrenal medulla,tumor of chemoreceptor system
    È­Çмö¿ëü°è Á¾¾ç(ûùùÊáôé»ô÷ͧ ðþåË)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 9
IGP intestinal glycoprotein
IIP idiopathic interstitial pneumonia; idiopathic intestinal pseudo-obstruction; increased intracranial ...
IMC indigent medical care; information-memory-concentration [test]; interdigestive migrating contraction...
INT intermediate; intermittent; intern, internship; internal; interval; intestinal; intima; p-iodonitrot...
Int international; intestinal
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 9
alpha-CGRP Alpha calcitonin gene-related peptide
ANP Alpha-atrial natriuretic peptide
alpha hANP Alpha-human atrial natriuretic peptide
APL Altered peptide ligands
A beta Amyloid beta peptide
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • trophoblastic tumor
    ¿µ¾ç¸· Á¾¾ç
  • tumor
    Á¾¾ç, Á¾Ã¢
    1. ¿¬Çϰųª ´Ü´ÜÇÏ¸ç ¿©·¯ °¡Áö ¸ð¾ç°ú Å©±â
  • tumor associated antigen
    ¾Ï °ü·Ã Ç׿ø
    ÀϺÎÀÇ Á¤»ó ¼¼Æ÷¿¡¼­¸¸ ¹ß°ßµÇ¾î ÀÖÀ¸³ª ¾Ï ¼¼Æ÷¿¡¼­µµ ¸¹Àº ¹üÀ§¿¡¼­ ¹ßÇöµÈ Ç׿ø, Á¤»ó ¼¼Æ÷¿¡¼­´Â ¹Ì·®ÀÌ Á¸ÀçÇϳª ¾Ï ¼¼Æ÷¿¡¼­´Â ´Ù·®ÀÌ °ËÃâµÇ´Â Ç׿ø, ±×·¯³ª °áÄÚ ¾Ï ƯÀÌÀûÀ̶ó°í ÇÒ ¼ö ¾ø´Â ¼ºÁúÀÇ Ç׿ø.
  • tumor growth
    Á¾¾ç ¼ºÀå
  • tumor like focal thickening
    Á¾¾ç °°Àº º´¼Ò ºñ´ë
  • tumor like swelling
    Á¾¾ç¼º ºÎÁ¾
  • tumor lysis syndrome
    Á¾¾ç ¿ëÇØ ÁõÈıº
    ¸Å¿ì ºü¸£°Ô ¼ºÀåÇÏ´Â ¾Ç¼º Á¾¾çÀÇ È¿°úÀûÀÎ È­ÇÐ ¿ä¹ý À¯µµ ÈÄ¿¡ ½ÉÇÑ °úÀλê Ç÷Áõ, °úÄ®·ý Ç÷Áõ, °ú¿ä»ê Ç÷Áõ, ÀúÄ®½· Ç÷ÁõÀ» ³ªÅ¸³»´Â ÁõÈıºÀ¸·Î ¼¼Æ÷ ¿ëÇØ·Î ÀÎÇÏ¿© ¼¼Æ÷³» »ê¹°ÀÌ À¯ÃâµÇ¾î ³ªÅ¸³­´Ù°í »ý°¢µÈ´Ù.
  • tumor mass
    Á¾¾ç
  • tumor necrosis factor
    Á¾¾ç ±«»ç ÀÎÀÚ
    TNF. Á¾¾ç¿¡ °ü°èÇϰí ÀÖ´Â ¸é¿ª°èÀÇ ¼¼Æ÷ÀÎ Á¾¾ç ħÀ±¼º ¸²ÇÁ±¸
  • tumor necrotizing factor
    Á¾¾ç ±«»ç ÀÎÀÚ
  • tumor of salivary gland
    ¼±¾ÏÁ¾
    Çô¹ØºÎ¿¡¼­ º¼ ¼ö ÀÖ´Â Çô¹Ø»ùÀÇ Àú·ù ³¶Æ÷·Î ¾ç¼ºÀÌ´Ù. Á¡¸· ¹Ù·Î ¾Æ·¡¿¡ Àִµ¥, ³»ºÎ°¡ Åõ¸íÇÏ°Ô ºñÃÄ º¸ÀÌ¸ç ¾à°£ Ǫ¸¥ºûÀ» ¶ì°í ÀÖ´Ù. ¹ßÀ°Àº ¿Ï¸¸Çϸç Áõ¼¼µµ ÀüÇô ¾øÀ¸³ª, ³Ê¹« Ä¿Áö¸é Çô¸¦ ÀÚÀ¯·Ó°Ô ¿òÁ÷ÀÏ ¼ö ¾ø¾î ¾ð¾î Àå¾Ö°¡ ÀϾ´Ù. ³»ºÎ¿¡´Â Åõ¸íÇϸç Á¡¸·µµ°¡ ¾à°£ ³ôÀº ħÀÌ µé¾î ÀÖ´Ù. Á¾¾çÀ» ¿ÏÀüÈ÷ Á¦°ÅÇÏÁö ¾ÊÀ¸¸é Àç¹ßÇϱ⠽±´Ù. ±× ¹ÛÀÇ ¾ç¼º Á¾¾çÀº ÀûÀ¸³ª ¼±Á¾, Áö¹æÁ¾, ½Å°æÃÊÁ¾, ¸²ÇÁ°üÁ¾, Ç÷°üÁ¾ µîÀÌ ÀÖ´Ù. ¨é ¾Ç¼º Á¾¾ç : ÇǸ·À» ¶Õ°í ÁÖÀ§¿¡ ħÀ±µÇ¹Ç·Î °¡µ¿¼ºÀÌ ¾ø°í µ¿ÅëÀÌ µû¸¥´Ù. ÆíÆò »óÇǾÏÀº ±Í¹Ø»ù¿¡ ¸¹°í ÅιػùÀÌ ±× ´ÙÀ½À¸·Î ¸¹´Ù. ƯÈ÷ 60´ë ³²¼º¿¡ ¸¹Àºµ¥, ħ»ù Á¾¾ç Áß¿¡¼­ °¡Àå ¾Ç¼ºÀÌ´Ù.
  • tumor of the salivary gland
    Ÿ¾×¼± Á¾¾ç
  • tumor secretion
    Á¾¾çÀÇ ºÐºñ
  • tumor size
    Á¾¾ç Å©±â
  • tumor specific transplantation
    Á¾¾ç ƯÀ̼º À̽Ä
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 8 ÆäÀÌÁö: 9
insulin c-peptide <investigation> A blood test which measures the amount of C-peptide in the blood. C-peptide is a byproduct of normal insulin production by the beta cells in the pancreas.
Normal values are 0.5 to 3.0 ng/ml. Normal levels indicate that the body is still producing its own insulin. Low levels indicate that the pancreas is producing little or no insulin. Elevations can be seen in cases of insulinomas and islet of Langerhans tumours.
(27 Sep 1997)
insulin-stimulating peptide <chemical> 71-amino acid containing peptide; corresponds to residues 115-143 and 144-184 of bovine serum albumin with the exception of a tyrosine insertion between residues 155 and 156; consists of two chains with mw 5000 and 3400 for each chain
Synonym: h-isp, insulin-stimulating protein
(05 Dec 1998)
islet amyloid peptide <hormone, protein> Peptide of 37 amino acids that selectively inhibits insulin stimulated glucose uptake in muscle. Structurally related to calcitonin gene-related peptide.
(15 Oct 1997)
eosinophil chemotactic peptide <protein> Tetrapeptides (of which two are identified: VGSE and AGSE) released by mast cells and that are said to both attract and activate eosinophils.
(18 Nov 1997)
UDP-N-acetylglucosamine-peptide beta-N-acetylglucosaminyltransferase <enzyme> Responsible for the addition of o-linked n-acetylglucosamine to proteins
Registry number: EC 2.4.1.-
Synonym: udp-glcnac-peptide-glcnac-transferase, glcnac transferase
(26 Jun 1999)
formyl peptide <biochemistry> Informal term for small peptides with a formylated N terminal methionine and usually a hydrophobic amino acid at the carboxy terminal end (fMetLeuPhe is the most commonly used).
These peptides stimulate the motor and secretory activities of leucocytes, particularly neutrophils and monocytes, that have a specific receptor (about 60 kD) of high affinity (Kd approximately 10exp 8M).
Leucocytes show chemotaxis towards formyl peptides but the term chemotactic peptides understates the range of activities the molecules will trigger. Thought to be synthetic analogues of bacterial signal sequences though this is unproven. The leucocytes of many animals (e.g. Pig, cow, chicken) do not respond.
(18 Nov 1997)
leader peptide <molecular biology> In the regulation of gene expression for enzymes concerned with amino acid synthesis in prokaryotes, the leader sequence codes for the leader peptide that contains several residues of the amino acid being regulated. Transcription is closely linked to translation and if translation is retarded by limited supply of amino acyl tRNA for the specific amino acid, the mode of transcription of the leader sequence permits full transcription of the operon genes, otherwise complete transcription of the leader sequence prematurely terminates transcription of the operon.
(18 Nov 1997)
lysergyl peptide synthetase <enzyme> Multifunctional enzyme which forms non-cyclol d-lysergyl peptide lactams; consists of two polypeptide chains - lps 1 binds the 3 amino acids (ala, phe and pro) of the peptide nucleus and lps 2 binds d-lysergic acid
Registry number: EC 6.3.2.-
Synonym: d-lysergylpeptide synthetase
(26 Jun 1999)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 9
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 9
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 9
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 9
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 9
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 9
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 9
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 9
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 9
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 9
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 9
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 9
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 9
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 9
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 9
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 9
ÅëÇÕ°Ë»ö ¿Ï·á